Emily Kaiser

Going forward, sozinibercept will be the official moniker of OPT-302, which holds fast track designation from the US Food and Drug Administration (FDA).

The submission of 24-month efficacy data from DERBY and OAKS is classified as a Major Amendment to the New Drug Application, which delays the PDUFA target action date until February 2023.

An end-of-week review of retina news and stories from October 29-November 3, 2022.

Scott Walter, MD, an investigator in the TENAYA and LUCERNE trials discusses the year 2 data for the treat-and-extend regimen of faricimab for the treatment of nAMD and DME.

Tom Ruggia, President and CEO of Samsara Vision, provides updates on the lead asset for late-state age-related macular degeneration: Smaller-incision, new generation, implantable miniature telescope (SING IMT).

A combination of posters, podium presentations, and instructional courses provided invaluable revelations to the ophthalmic community.

At AAO 2022, Justis Ehlers, MD, presented a talk entitled, "Defining the Fluid Problem in Neovascular AMD: To Dry or Not to Dry?"

Roger A. Goldberg, MD, MBA, discusses his 2022 AAO poster: "T&E-Based Personalized Treatment Interval Dynamics in the YOSEMITE/RHINE Trials of Faricimab in DME."

Results from our recent poll regarding AAO 2022 attendance indicate that most ophthalmologists and retina specialists plan to participate in the Annual Meeting in person in Chicago, Illinois.

Roche’s treatment of faricimab is the first and only FDA-approved medicine targeting two distinct pathways, angiopoietin (Ang)-2 and vascular endothelial growth factor (VEGF)-A, that often cause retinal diseases that may cause visual loss.

A poll for retina specialists regarding their attendance at the 2022 American Academy of Ophthalmology Meeting in Chicago, Illinois. The poll is now closed.

A synopsis of the findings presented at EURETINA 2022 for ophthalmologists and retina specialists.

Tunde Peto, MD, PhD, shares some ophthalmic initiatives she's excited about in light of EURETINA 2022.

Tunde Peto, MD, PhD, discussed two of her presentations at EURETINA 2022: "UK Biobank retinal imaging grading: methodology, baseline characteristics and findings for common ocular diseases" and "Retinal phenotyping of different variants of Alzheimer’s disease using ultra-widefield imaging."

Dara Conlon, Executive Vice President of EURETINA, and Prof. Anat Loewenstein, General Secretary of EURETINA, discuss some key features of this year's Congress.

Results from our recent poll regarding EURETINA 2022 attendance indicate that most ophthalmologists and retina specialists plan to participate in the annual Congress in person in Hamburg, Germany.

A poll for retina specialists across the globe as the EURETINA 2022 meeting approaches. This poll is now closed.

Nancy Lurker, CEO of EyePoint Pharmaceuticals, shares the 12-month safety data from the DAVIO trial, investigating EYP-1901 for the treatment of wet age-related macular degeneration (AMD) and nonproliferative diabetic retinopathy.

Victor Gonzalez, MD, shares updates from the Phase 4 Paladin study regarding the safety and efficacy of fluocinolone in diabetic macular edema.

Claire Gelfman, PhD, Chief Scientific Officer of Foundation Fighting Blindness, supplies a brief overview of the foundation's aims and updates on retinal disease research.

At ASRS 2022, John Kitchens, MD, presented, “Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab."

Kerrie Brady, CEO of OcuTerra Therapeutics, shares an update on their eye drop-based integrin inhibitor, which is intended to be a novel therapy for diabetic retinopathy.

At ASRS 2022, Sunir Garg, MD, FACS, discussed his talk entitled, “Impact of Delay in Repair of Rhegmatogenous Retinal Detachment: Real-World Outcomes from the IRIS Registry.”

At ASRS 2022, Sally Ong, MD, presented a talk entitled, “Vitrectomy vs Vitrectomy With Scleral Buckling in the Treatment of Giant Retinal Tear Related Retinal Detachments: International Multicenter Study.” Here she shares the biggest takeaways.

The American Society of Retina Specialists held its 40th Annual Meeting in New York, New York, from July 13-16, 2022. While data was presented for all topics in retina, new revelations in age-related macular degeneration, diabetic retinopathy, and diabetic macular edema dominated the conversation.

Rahul Khurana, MD, discusses his 2022 ASRS talk, “Phase 2 Study of THR-149, a Plasma Kallikrein Inhibitor in Patients With DME Who Respond Suboptimally to Anti-VEGF Treatment (Month 6 Results of Part A of the KALAHARI Study),” which he presented in New York City, New York.

At ASRS in New York, Matthew Starr, MD, presented, “Factors Associated With Fluctuations in Central Subfield Thickness in Patients With Diabetic Macular Edema Using 2 Clinical Trial Databases.”

At ASRS in New York City, Charles Wykoff, MD, presented a talk entitled, “Suprachoroidal Delivery of RGX-314 Gene Therapy for Diabetic Retinopathy: Phase II ALTITUDE Study.” The trial demonstrated large improvements for patients with diabetic macular edema (DME) and non-proliferative diabetic retinopathy (NPDR), with notable improvements according to the Diabetic Retinopathy Severity Scale (DRSS).

At ASRS 2022 in New York City, New York, Rishi Singh, MD, is presenting, “12-Month Results of EYP-1901 Vorolanib in a Bioerodible Durasert Insert for nAMD: The DAVIO Trial.” The Phase 1 trial showed a reduction in treatment burden over 12 months as well as a favorable safety profile.

Christopher Henry, MD, presented a talk entitled, “Efficacy of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in the Treatment of Macular Edema in Patients With Chronic Uveitis,” at ASRS 2022 in New York City, New York.